Health
Drug Repurposing in Cancer Treatment: Emerging Strategies and Promising Developments
Cancer continues to be one of the leading causes of death globally, with millions of new diagnoses each year. The conventional process of developing new cancer drugs is notoriously slow and costly, often requiring more than a decade and billions of dollars to reach patients. In response, drug repurposing, also called drug repositioning, has gained significant attention as a practical alternative. This strategy finds new anticancer applications for medications already approved for other medical conditions. Because these drugs have established safety records, known dosing guidelines, and existing production methods, repurposing can dramatically shorten development timelines and lower financial barriers compared with creating entirely new compounds. Organizations focused on innovative and integrative oncology approaches, such as Sanare Lab, offer valuable insights and resources for exploring experimental protocols in this rapidly evolving field.
One especially interesting avenue within drug repurposing is methylene blue cancer research. This compound, long used as a dye and as a treatment for methemoglobinemia, is now under investigation for possible anticancer effects. Researchers have examined methylene blue in photodynamic therapy, where it serves as a photosensitizer. When activated by specific wavelengths of light, it generates reactive oxygen species that can damage and kill cancer cells. Laboratory and animal studies have shown reductions in tumor volume in models of colorectal cancer, breast cancer, and melanoma, particularly when combined with other treatment approaches. These findings illustrate how a familiar, inexpensive compound might provide new ways to target resistant or difficult-to-treat tumors.
Why Drug Repurposing Matters in Oncology
The main advantage of repurposing lies in its efficiency. Traditional drug discovery begins with identifying a new molecule, followed by years of laboratory testing, animal studies, and multi-phase human trials to confirm both safety and effectiveness. Repurposed drugs skip much of this early work because regulators have already approved them for their original use. Investigators can therefore move more quickly to testing whether the drug works against cancer, often starting directly in mid- or late-stage clinical trials.
Cost is another critical factor. The failure rate in new oncology drug development frequently exceeds ninety percent, driving up expenses that are eventually reflected in treatment prices. Many repurposed candidates are off-patent generics, which means they can be produced and distributed at a fraction of the cost of branded medicines. With cancer rates expected to keep rising worldwide, especially in low- and middle-income countries, affordable options derived from existing drugs could help close gaps in access to effective care.
Well-Known Examples of Repurposed Drugs in Cancer
Drug repurposing already has several important successes in oncology. Thalidomide, originally marketed as a sedative and later withdrawn because of severe birth defects, was rediscovered in the late 1990s for multiple myeloma. Its ability to block new blood vessel formation in tumors made it a valuable addition to treatment regimens, and it remains widely used today, frequently combined with other agents.
All-trans retinoic acid, first studied for skin conditions, transformed outcomes in acute promyelocytic leukemia by prompting malignant cells to mature into normal ones. When paired with arsenic trioxide, another agent with a long history in traditional medicine, the combination now achieves very high remission rates in this once-deadly subtype of leukemia.
Metformin, the most commonly prescribed medication for type 2 diabetes, has attracted attention after population studies showed lower cancer rates among diabetic patients taking it. The drug appears to interfere with energy metabolism in cancer cells by activating a key regulatory pathway that slows uncontrolled growth. Multiple clinical trials have tested metformin as an add-on to standard chemotherapy or radiation in breast, prostate, colorectal, and other cancers, with some studies reporting improved survival or reduced recurrence.
Statins, best known for lowering cholesterol, have also been evaluated for anticancer effects. By blocking an enzyme involved in cholesterol synthesis, they disrupt signaling pathways that cancer cells use to grow and spread. Large observational studies have linked statin use to modestly reduced risk of certain cancers, and ongoing research continues to explore their role as adjunctive therapy.
Other candidates include antiparasitic agents such as mebendazole, which interfere with the structural framework cancer cells need to divide, and the anticonvulsant valproic acid, which modifies gene expression by inhibiting enzymes that control DNA packaging. Both have shown activity in laboratory models of colorectal, brain, and pancreatic cancers, and early human studies are underway.
Spotlight on Methylene Blue in Cancer Research
Returning to methylene blue, this compound continues to generate interest because of its diverse biological effects. Beyond its role in photodynamic therapy, methylene blue can influence cancer cell metabolism. Many tumors depend heavily on glycolysis for energy production even when oxygen is available, a phenomenon known as the Warburg effect. Methylene blue appears to disrupt this altered metabolism, potentially starving cancer cells of fuel. In preclinical models of ovarian cancer, particularly those resistant to platinum-based chemotherapy, methylene blue slowed tumor progression more effectively than standard drugs in some experiments.
When used in photodynamic therapy, methylene blue tends to concentrate in mitochondria, the energy-producing structures inside cells. Light exposure then triggers the release of damaging oxygen radicals, leading to cell death through apoptosis. Systematic reviews of animal studies have reported consistent tumor shrinkage across several cancer types, including breast carcinoma and skin melanoma, often with low toxicity at the doses tested.
Methylene blue may also improve tumor oxygenation, which could make radiotherapy more effective. Poorly oxygenated regions within solid tumors are notoriously resistant to radiation, so any agent that increases oxygen availability has therapeutic potential. In addition, surgeons sometimes use methylene blue injections to map sentinel lymph nodes during breast cancer operations, helping to identify the first nodes where cancer is most likely to spread.
Despite these encouraging signals, methylene blue remains experimental for most cancer applications. While side effects are generally mild at therapeutic doses, interactions with certain medications require careful monitoring. Large, well-controlled clinical trials are still needed to determine whether the promising laboratory and early human data translate into meaningful benefits for patients.
Remaining Challenges and the Path Forward
Drug repurposing is not without obstacles. Because many candidate drugs are generic, pharmaceutical companies have limited financial incentive to fund expensive trials for new indications. Regulatory agencies sometimes require nearly as much evidence for a repurposed use as for a completely novel drug, which can slow progress. Off-label prescribing also raises questions about informed consent and standardized protocols when robust data are lacking.
Collaborative efforts are helping to address these barriers. Networks of researchers, clinicians, and advocacy groups are systematically reviewing existing drugs for anticancer potential, prioritizing those with the strongest preclinical rationale, and pushing for well-designed trials. Advances in computational biology allow scientists to screen thousands of compounds against cancer-related targets much faster than before, narrowing the list of drugs worth testing in the laboratory or clinic.
Looking ahead, combination strategies are likely to dominate. Pairing repurposed agents with immunotherapy, targeted therapies, or conventional chemotherapy could produce synergistic effects greater than any single treatment alone. Personalized approaches that match specific drugs to the molecular features of an individual’s tumor will further refine their use.
In summary, drug repurposing offers a realistic and increasingly important strategy for improving cancer care. From established successes like thalidomide and metformin to emerging candidates such as methylene blue, the field demonstrates that familiar medicines can sometimes deliver unexpected benefits against one of medicine’s toughest challenges. Sustained investment in rigorous clinical research and broader collaboration will determine how much further this approach can take us toward more effective, accessible treatments for patients everywhere.
Health
AI Speeds Up Ebola Response in Congo, but Experts Warn of Healthcare Risks
Artificial intelligence is helping health authorities respond more quickly to the Ebola outbreak in the Democratic Republic of Congo (DRC), cutting the time needed to prepare a situation report from a full working day to about an hour. However, experts warn that concerns over transparency, reliability and accountability must be addressed before the technology becomes more widely used in healthcare.
Since May, health workers in the DRC have been responding to an outbreak of the Bundibugyo strain of the Ebola virus. Teams visit communities, provide advice, record deaths and recoveries, and refer people with suspected symptoms to medical facilities.
Information collected by these workers has been digitised and analysed using Anthropic’s Claude artificial intelligence model. The initiative involved the Coalition for Epidemic Preparedness Innovations (CEPI), the World Health Organization’s Regional Office for Africa and the country’s National Institute of Biomedical Research (INRB).
The system helps identify people who may have been exposed to the virus, trace contacts and locate potential outbreak hotspots. This information allows authorities to prepare medical supplies and position resources in areas considered at higher risk.
Marie Roseline Darnycka Belizaire, director for emergency preparedness and response at the WHO Regional Office for Africa, said the technology had reduced the time required to produce situation reports to around one hour.
Speaking at the World Health Summit, she said AI could help health authorities assess the spread of an outbreak more quickly and direct medical assistance where it was needed most.
Supporting overstretched healthcare systems
Thomas Zapata, director of the WHO Academy in Lyon, said AI could help address growing demand for healthcare amid persistent shortages of medical staff and resources.
However, he cautioned against treating the technology as a solution in itself, arguing that it must be integrated into existing health systems and support the work of healthcare professionals.
AI could reduce administrative workloads, improve diagnostic processes and assist clinical decision-making, allowing medical staff to spend more time examining patients, listening to their concerns and arranging appropriate treatment.
Cecilia Mbaka, a senior technical adviser for health and emergencies at aid organisation CARE, said the technology could be particularly useful for repetitive tasks and information processing. She stressed that its value should be measured by whether it improves care and gives medical professionals more time to attend to patients.
In the DRC, however, shortages of equipment and limited public confidence in healthcare facilities remain major challenges. Epidemiologist Maximilian Gertler has estimated that around half of deaths in villages occur outside medical facilities, highlighting difficulties in accessing formal care.
Germany recently increased its assistance to the country by €21 million.
Questions over transparency and reliability
Despite the potential benefits, experts warn that many AI systems cannot clearly explain how they reach particular results.
Thomas Thesen, a professor of medical education and informatics at Dartmouth University’s Geisel School of Medicine, said AI models were highly effective at identifying patterns but often struggled to explain what those patterns meant.
This creates concerns when AI systems offer diagnoses or treatment recommendations. Medical professionals need to assess whether a recommendation is appropriate for an individual patient and understand its limitations. Questions also remain over who should be held responsible when an AI-generated recommendation is wrong.
AI should not replace medical education
Experts also warn that excessive reliance on AI could weaken the training of future healthcare professionals.
Thesen cited research suggesting that students who used AI chatbots to find information developed more superficial knowledge than those who relied on conventional search methods.
He said independent learning and mental effort were essential to retaining information, particularly in medicine, where professionals must make decisions even when technological assistance is unavailable.
The Ebola response demonstrates how AI can help process information quickly during emergencies. Experts say its wider use in healthcare will depend on maintaining human oversight, protecting patients and ensuring that technology strengthens, rather than replaces, professional judgement.
Health
Portuguese Teenagers Report Lower Drug and Alcohol Use, but High-Risk Behaviour Persists
Portuguese teenagers are reporting lower levels of alcohol and drug use and fewer problems linked to addictive behaviours, but risks are becoming increasingly concentrated among young people facing multiple personal and social difficulties, according to a new study.
The findings come from the 2024 Study on Alcohol, Tobacco, Drugs and Other Addictive Behaviours (ECATD-CAD), conducted by the Institute for Addictive Behaviours and Dependencies (ICAD). The research examines addictive behaviours among pupils aged 13 to 18 attending state schools across Portugal.
Compared with the previous study in 2019, the latest results show a consistent decline in reported problems, including violence, accidents, hospitalisations, risky sexual behaviour and other incidents with potentially serious consequences.
Researchers linked the broader improvement to several protective factors. Students reported better academic performance, closer parental supervision and fewer nights out, suggesting that changes in family and school environments may be helping reduce risky behaviour.
However, ICAD warned that the overall decline does not mean the problem has disappeared. The most serious behaviours are increasingly concentrated in a relatively small group of adolescents who face greater individual and social vulnerabilities.
Recent alcohol consumption and, particularly, illicit drug use remain strongly associated with problematic situations. Young people who use psychoactive substances report higher rates of risky sexual behaviour, violence between individuals, accidents and trouble with the police.
The report noted that these problems do not necessarily occur immediately after substance use, but the association remains significant.
Combining alcohol with illicit drugs appears to carry additional risks. Adolescents who reported recent use of both substances experienced higher levels of accidents, police-related problems, cyberbullying and risky sexual behaviour than those who consumed alcohol alone.
Alcohol use also raises concerns about why some teenagers drink. While pleasure, entertainment and socialising remain the main motivations, a significant proportion said they consumed alcohol to forget their problems. ICAD identified this as a warning sign associated with potentially harmful drinking patterns and dependence.
Cannabis use presented a mixed picture. Although most users showed no indicators of dependency risk, the proportion classified as being at high risk increased, alongside growth in the group with no identified risk.
Social media remained the main concern among behaviours not involving substances. A significant number of young people acknowledged spending excessive time on these platforms. Indicators of problematic electronic gaming remained broadly stable, while gambling for money became more prevalent among adolescents, despite a slight decline in some indicators of problematic gambling.
The study also identified differences between boys and girls. Boys were more likely to report problems with the police, risky gaming and gambling. Girls reported higher levels of problematic social media use and were more likely to use alcohol to cope with emotional difficulties.
Family circumstances and wellbeing were also important. Low academic achievement, limited parental supervision, frequent nights out and poorer physical and emotional health were associated with greater risk. Better school performance, stronger parental involvement and improved wellbeing appeared protective.
Regional differences were also evident. Alentejo recorded the highest concentration of unfavourable indicators, followed by the Azores. Lisbon, which showed the greatest vulnerability in the 2019 study, no longer held that position.
ICAD’s findings point to the need for targeted support for vulnerable adolescents, even as overall patterns of substance use and related problems improve.
Health
Plague Fears Return After Russian Death, but Europe Faces Very Low Risk
The death of a scientist in Russia’s Siberian region of Irkutsk has revived concerns about plague, but health authorities say there is currently no evidence of an outbreak or sustained transmission in Europe.
The woman died from pneumonia of unknown origin, prompting speculation that she could have contracted pneumonic plague. Russian authorities have said no plague cases have been confirmed in the region, while tests conducted on people who had contact with the woman were negative.
The World Health Organization has asked Russia for additional information about the incident and offered assistance to local health authorities.
Plague is caused by the bacterium Yersinia pestis, which remains present in wild animal populations in parts of the world. It is commonly associated with rodents and the fleas that live on them. People can become infected through bites from infected fleas, contact with tissues or bodily fluids from infected animals, or respiratory particles from people suffering from pneumonic plague.
For Spain and most of Europe, however, the current risk is considered very low. The European Centre for Disease Prevention and Control says routine transmission has not been recorded in Europe for more than five decades.
That does not mean the bacterium has disappeared. Its continued presence in animal reservoirs means isolated human infections remain possible, particularly in areas where infected wildlife and fleas are found.
Spain has maintained epidemiological surveillance despite the absence of locally acquired cases for decades. In April 2026, its Public Health Commission updated the national plague protocol, including case definitions, epidemiological information and procedures for investigating suspected infections.
European authorities have also been monitoring the Siberian incident. The European Union discussed the case at a Health Security Committee meeting on October 7, while the ECDC said there was no evidence of secondary cases or sustained person-to-person transmission.
The WHO has assessed the risk to the European region as very low.
Plague continues to occur in parts of Africa, Asia and the Americas. According to the WHO, most reported human cases between 2019 and 2025 were concentrated in Madagascar and the Democratic Republic of the Congo. Madagascar records bubonic plague cases during its annual epidemic season, generally from September to April. In the United States, about seven human cases are reported each year, mainly in rural areas of western states.
The disease can occur in bubonic, pneumonic or septicaemic forms. Bubonic plague usually causes fever and painful swollen lymph nodes after an infected flea bite. Pneumonic plague affects the lungs and can spread between people through respiratory particles. Septicaemic plague occurs when the infection enters the bloodstream.
Modern antibiotics can successfully treat plague, but early diagnosis is critical. Health surveillance, rapid identification and treatment remain important in preventing isolated infections from developing into wider outbreaks.
-
Entertainment2 years agoMeta Acquires Tilda Swinton VR Doc ‘Impulse: Playing With Reality’
-
Sports2 years agoChina’s Historic Olympic Victory Sparks National Pride Amid Controversy
-
Business2 years agoSaudi Arabia’s Model for Sustainable Aviation Practices
-
Business2 years agoRecent Developments in Small Business Taxes
-
Home Improvement2 years agoEffective Drain Cleaning: A Key to a Healthy Plumbing System
-
Politics2 years agoWho was Ebrahim Raisi and his status in Iranian Politics?
-
Sports2 years agoKeely Hodgkinson Wins Britain’s First Athletics Gold at Paris Olympics in 800m
-
Business2 years agoCarrectly: Revolutionizing Car Care in Chicago
